A Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine
Open Access
- 28 February 2019
- journal article
- editorial
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 17 (1) , 134-138
Abstract
Yakup Albayrak, Murat Beyazyüz, Özlem Abbak, Ece Altındağ. Clin Psychopharmacol Neurosci 2019;17:134-8. https://doi.org/10.9758/cpn.2019.17.1.134Keywords
This publication has 34 references indexed in Scilit:
- Beneficial Effects of the Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia in Patients With Postpsychotic Depressive Disorder of SchizophreniaThe Primary Care Companion For CNS Disorders, 2012
- Beneficial Effects of Fluvoxamine for Chorea in a Patient With Huntington’s DiseaseThe Primary Care Companion For CNS Disorders, 2012
- Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disordersJournal of Cellular and Molecular Medicine, 2011
- Paliperidone-Related Rabbit SyndromeJournal of Clinical Psychopharmacology, 2011
- Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disordersExpert Opinion on Therapeutic Targets, 2011
- Molecular mechanisms involving sigma receptor–mediated induction of MCP-1: implication for increased monocyte transmigrationBlood, 2010
- Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five casesAnnals of General Psychiatry, 2010
- Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptorsAnnals of General Psychiatry, 2010
- The pharmacology of sigma-1 receptorsPharmacology & Therapeutics, 2009
- Measurement of Anticholinergic Effects of Psychotropic Drugs in HumansPharmacopsychiatry, 2005